Acromegaly – Medxy AI

Diabetes & Endocrinology news Pathology & Lab Medicine

Histological Subtypes of Pituitary Adenomas: Their Role in Acromegaly Surgical Outcomes and Disease Control

By MedXY 09/21/2026

This study evaluates how different pituitary adenoma histological subtypes influence remission and disease control in acromegaly post-surgery, finding no significant differences though sparsely granulated adenomas show a trend toward lower remission.

Diabetes & Endocrinology news Radiology

Acromegaly Diagnosis

By MedXY 06/10/2026

Acromegaly is often diagnosed late because symptoms are subtle. Serum IGF-I is the best screening test, OGTT confirms GH excess, and MRI localizes pituitary tumors. New AI and imaging tools may improve earlier detection.

Diabetes & Endocrinology news Psychiatry

Biochemical Control Is Not Enough: Why Acromegaly Still Carries Major Quality-of-Life and Treatment Burden

By MedXY 06/09/2026

A 2026 review shows that many patients with acromegaly remain symptomatic and functionally impaired despite biochemical control, underscoring the need for routine patient-reported outcomes and lower-burden, multidisciplinary care.

Diabetes & Endocrinology news Radiology

Pituitary Adenoma Imaging as a Key Determinant of Acromegaly Diagnosis and Outcomes

By MedXY 06/07/2026

High-quality pituitary imaging is essential for diagnosing and managing acromegaly, localizing somatotroph adenomas, guiding surgery or radiotherapy, and reducing treatment-related harm. A standardized, tiered MRI-based approach improves accuracy and supports better outcomes.

Diabetes & Endocrinology news

Deciphering the cAMP Nexus: The Molecular Architecture of Sporadic Somatotroph Adenomas

By MedXY 03/15/2026

A comprehensive analysis of the cAMP-driven pathogenesis of non-familial somatotroph adenomas, exploring how GNAS mutations and DNA damage response pathways dictate clinical behavior and therapeutic sensitivity in acromegaly.